Cell and Gene Outsourcing
-
Clinical Research As A Delicate Ecosystem
4/18/2024
Making the right outsourcing decision can significantly contribute to the success and growth of your program, providing essential support and resources that empower it to thrive in its objectives and endeavors.
-
Mastering Scale: Solutions For Overcoming Scalability Challenges In Cell And Gene Therapy Manufacturing
4/17/2024
Advanced therapies present challenges when it comes to scaling up production. Explore how collaboration, investment in R&D, and process optimization are paving the way for new treatment options.
-
Stand-Alone Fill & Finish Service Offering
4/17/2024
Review our technical capabilities and specifications and discover how a partner with fill-finish services designed to take advantage of 100% of the product can guide your product to commercial success.
-
Efficient Viral Vector Production: A Rentschler Collaboration Story
4/17/2024
Learn how a collaboration between Cytiva and Rentschler Biopharma facilitates the efficient and flexible production of viral vectors.
-
Demonstrating Value Throughout The Product Development Lifecycle
4/15/2024
Examine how a partner with extensive capabilities and expertise adds value to drug development and helps to solve complex formulation, analytical, and manufacturing challenges our clients face.
-
Supporting Cell And Gene Therapy Manufacturing
4/15/2024
Ensuring the safety and efficacy of cell and gene therapy treatments necessitates rigorous quality control. See how an outsourcing partner can help you deliver safe, efficacious therapies to patients.
-
Testing Solutions For RNA-Based Products
4/12/2024
RNA-based therapeutics have become structurally complex and require sophisticated analytical methodologies. Learn how SGS can help you meet regulatory standards and ensure product efficacy.
-
Testing Solutions For Viral Vector-Based Products
4/12/2024
Developing viral vector therapies requires a rigorous process to ensure safety and efficacy. Learn how SGS can help ensure the effectiveness and safety of viral vector-based drug products.
-
Why Early Market Access Planning Is Crucial In CGT Commercial Strategy
4/12/2024
Bringing cell and gene therapies (CGTs) to market and ensuring patient access is a complex process. Discover how developing a market access strategy and partnering with experts can help.
-
Protein Characterization And Biosafety Testing Services
4/8/2024
Discover a partner with extensive expert knowledge to support your new biological entity (NBE) or biosimilar with off-the-shelf and custom assays, as well as regulatory-compliant biosafety testing.